Irish back pain group Mainstay Medical raises €115m to fund expansion
Two new investors lead funding round as company looks to accelerate commercial rollout in key US market as well as Europe and Australia
Mainstay Medical
Back pain device group Mainstay Medical raises $108m
Funding will drive commercialisation of Reactiv8 in critical US market
Fountain closes third life sciences fund after raising €125m
Group eyeing up to 10 investments, mostly in therapeutics and medical device sectors
Mainstay Medical gets approval to sell back pain device in US
Company secures FDA approval for its flagship medical device called ReActiv8
Irish back pain medical device group receives important approval in Australia
Mainstay Medical’s flagship product is now eligible for reimbursement from private health funds
Irish back pain medical device group to pull stock market listings
Mainstay Medical cites poor liquidity in shares and cost for decision to take business private
Mainstay Medical pares losses by over one-third in 2019
Revenue at Irish medical device company targeting chronic back pain almost doubles
Hope for US-China trade deal cheers markets
Holiday week sees thin trading in Dublin as rise in online shopping boosts Amazon
Mainstay meets with FDA on ReActiv8 application
‘Day 100’ meeting reviews status of application’s review
Mainstay Medical doubles revenue in first six months
Company submits application for pre-market approval to US regulator
Irish VC group Fountain Healthcare Partners raises €118m
Group beats €100m target and intends to invest the bulk of the fund in Europe and US
Shares crash as Mainstay back pain device fails clinical trial
Company insists other data support case for its implanted electrical stimulation device
Mainstay on track to announce trial results as revenues rise
Company awaits data as it looks to roll-out ReActive8 device to patients in the US
Irish tech firms see VC funding fall for first time since 2011
Call for Government action after funding falls 9% to €453m in first six months of 2018
Mainstay Medical appoints new chief financial officer
Matthew Onaitis joins medical device company from Cidara Therapeutics
Mainstay Medical hits milestone in key US clinical trial
Group completes back pain neurostimulator implants in all 204 patients enrolled in test for device
Mainstay hits delay in Australian approval for ReActiv8
Company will wait until end of US trial on back pain therapy for new clinical data requested by authorities
Mainstay Medical raises €30m from new share placing
Company says five centres in Germany and Ireland have implanted patients with ReActiv8
Mainstay Medical passes ‘important milestone’ in clinical trials
Firm aims to bring its new therapy for chronic lower back pain to key US market
Mainstay Medical losses increase by 50%
Irish company positive about clinical trial stemming from its ReActiv8-B product
Mainstay Medical to seek further funding as full-year losses mount
Dublin-listed medical devices firm recently made its first commercial sale in Germany
The major business events happening this week
For Your Diary: INM results, UK retail figures and Girls in Tech conference
Mainstay Medical sells its first ReActiv8 implant for back pain
Iseq-listed medical device firm targets commercial growth and completion of US clinical trials
Mainstay Medical seeks approval to sell ReActiv8 in Australia
Dublin-listed firm pushes ahead with plans to commercialise back pain treatment
Irish tech firms raise €734m in first nine months of 2016
Survey shows level of investment in Irish tech companies has risen sharply in recent years
Mainstay Medical adds eighth US patent to its IP portfolio
Company’s flagship product ReActiv8 won European approval earlier this year
Irish-headquartered Mainstay posts first-half loss of $8m
Mainstay raised €30m funding in June through placing of new shares
Irish-headquartered Mainstay sees losses narrow to $13m
Operating expenses also decline while R&D and clinical and regulatory costs rise
Buzz builds as Dublin hosts Innovation in Medtech conference
Venture capital firms with more than €13bn in funds will seek investment opportunities
Mainstay Medical sees drop in full-year operating expenses
Dublin-listed medical devices firm says plans progressing to bring ReActiv8 to market
Mainstay Medical to seek European approval for device
A trial of 47 patients showed after three months, 63 per cent reported clinically important improvement in back pain
Irish medical firm Mainstay receives third US patent
Dublin-listed company pushing forward with plans to bring Reactiv8 to market
Mainstay Medical agrees debt facility of up to $15m
Company will use money to build momentum towards commercialisation of ReActiv8
Mainstay Medical says 2014 was ‘significant year’ for firm
Irish medical devices company pushes ahead with clinical trials for ReActiv8
Mainstay Medical reports progress with clinical trial
Dublin-headquartered medtech firm says 25 subjects implanted in ReActive8 trial so far
Number of trades dealt on Irish Stock Exchanges soars
The total value of trades rose 7 per cent to €1.8 billion in the first six months of the year
Mainstay Medical raises €18m in €90m floatation in Paris and Dublin
Proceeds will fund clinical trials of back pain device as shares float at lower end of guided range
Medical device group Mainstay plans €100m flotation
Irish back pain group hopes to raise €20m to fund clinical trials and other costs of bringing device to market
Back pain group plans stock market float
Mainstay Medical looking to list in Paris and Dublin as it trials first product
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Stardust
Inquests into the nightclub fire that led to the deaths of 48 people
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices